The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 7, 2012, Pages 1096-1104

  Furuya, Kazuyuki ^a,b   Yamamoto, Noriko ^a   Ohyabu, Yuki ^a   Makino, Akito ^a,c   Morikyu, Teruyuki ^a   Ishige, Hirohide ^a   Kuzutani, Kazuya ^a   Endob, Yasuhisa ^b  

^a KAKEN PHARMACEUTICAL CO LTD   (Japan)

^b KYOTO INSTITUTE OF TECHNOLOGY   (Japan)

^c TEIJIN PHARMA LIMITED   (Japan)

Author keywords

Additive effect; Bone anabolic; Selective androgen receptor modulator

Indexed keywords

ALENDRONIC ACID; ANDROGEN RECEPTOR; ANDROSTANOLONE; N [2 (8 CYANO 1 FORMYL 2,3,3A,4,5,9B HEXAHYDRO 1H PYRROLO[3,2 C]QUINOLIN 4 YL) 2 METHYLPROPYL] 4,6 DIFLUOROBENZOFURAN 2 CARBOXYAMIDE; PARATHYROID HORMONE[1-34]; RALOXIFENE; S 101479; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE DENSITY; BONE MASS; BONE MINERAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; RAT;

ALENDRONATE; ANDROGENS; ANIMALS; BENZOFURANS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG INTERACTIONS; FEMALE; MALE; PARATHYROID HORMONE; QUINOLINES; RABBITS; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, STEROID; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TERIPARATIDE;

EID: 84863549060     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00054     Document Type: Article

References (45)

1. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab., 81, 4358-4365 (1996).
2. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab., 89, 503-510 (2004).
3. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose - response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab., 281, E1172-E1181 (2001).
4. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. J. Endocrinol. Invest., 32, 704-716 (2009).
5. Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG, Nieschlag E. Issues in testosterone replacement in older men. J. Clin. Endocrinol. Metab., 83, 3435-3448 (1998).
6. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med., 350, 482-492 (2004).
7. Davis SR, Tran J. Testosterone influences libido and well being in women. Trends Endocrinol. Metab., 12, 33-37 (2001).
8. Redmond GP. Androgens and women's health. Int. J. Fertil. Womens Med., 43, 91-97 (1998).
9. Chesnut CH 3rd, Ivey JL, Gruber HE, Matthews M, Nelp WB, Sisom K, Baylink DJ. Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism, 32, 571-580 (1983).
10. Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG. Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas, 17, 211-219 (1993).
11. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J. Reprod. Med., 44, 1012-1020 (1999).
12. Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin. Liver Dis., 7, 230-236 (1987).
13. Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull., 26, 1563-1569 (2003).
14. Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR Jr, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology, 148, 4-12 (2007).
15. Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology, 145, 5420-5428 (2004).
16. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, López FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A. An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology, 148, 363-373 (2007).
17. Schmidt A, Harada S, Kimmel DB, Bai C, Chen F, Rutledge SJ, Vogel RL, Scafonas A, Gentile MA, Nantermet PV, McElwee-Witmer S, Pennypacker B, Masarachia P, Sahoo SP, Kim Y, Meissner RS, Hartman GD, Duggan ME, Rodan GA, Towler DA, Ray WJ. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J. Biol. Chem., 284, 36367-36376 (2009).
18. Russell RG. Bisphosphonates: from bench to bedside. Ann. N. Y. Acad. Sci., 1068, 367-401 (2006).
19. Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone, 40, 843-851 (2007).
20. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 344, 1434-1441 (2001).
21. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab., 85, 2129-2134 (2000).
22. Vajda EG, Hogue A, Griffiths KN, Chang WY, Burnett K, Chen Y, Marschke K, Mais DE, Pedram B, Shen Y, van Oeveren A, Zhi L, López FJ, Meglasson MD. Combination treatment with a selective androgen receptor modulator (SARM) and a bisphosphonate has additive effects in osteopenic female rats. J. Bone Miner. Res., 24, 231-240 (2009).
23. Miyakoshi N. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr. Pharm. Des., 10, 2615-2627 (2004).
24. Nakayama O, Arakawa H, Yagi M, Tanaka M, Kiyoto S, Okuhara M, Kohsaka M. WS-9659 A and B, novel testosterone 5 alphareductase inhibitors isolated from a Streptomyces. III. Biological characteristics and pharmacological characteristics. J. Antibiot. (Tokyo), 42, 1235-1240 (1989).
25. McGuire JL, DeDella C. In vitro evidence for a progestogen receptor in the rat and rabbit uterus. Endocrinology, 88, 1099-1103 (1971).
26. Wrange O, Carlstedt-Duke J, Gustafsson JA. Purification of the glucocorticoid receptor from rat liver cytosol. J. Biol. Chem., 254, 9284-9290 (1979).
27. Horiuchi M, Kohashi N, Nishiyama H, Hama J, Takenaka T, Kondo H, Katori R. Regulation of aldosterone receptor in rat kidney cytosol by atrial natriuretic factor. Hypertension, 13, 334-340 (1989).
28. Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108 (1973).
29. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT. Pharmacodynamics of selective androgen receptor modulators. J. Pharmacol. Exp. Ther., 304, 1334-1340 (2003).
30. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm. Res., 24, 328-335 (2007).
31. Martinborough E, Shen Y, Oeveren A, Long YO, Lau TL, Marschke KB, Chang WY, López FJ, Vajda EG, Rix PJ, Viveros OH, Negro-Vilar A, Zhi L. Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators. J. Med. Chem., 50, 5049-5052 (2007).
32. Schmidt A, Harada S, Kimmel DB, Bai C, Chen F, Rutledge SJ, Vogel RL, Scafonas A, Gentile MA, Nantermet PV, McElwee-Witmer S, Pennypacker B, Masarachia P, Sahoo SP, Kim Y, Meissner RS, Hartman GD, Duggan ME, Rodan GA, Towler DA, Ray WJ. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J. Biol. Chem., 284, 36367-36376 (2009).
33. Schmidt A, Kimmel DB, Bai C, Scafonas A, Rutledge S, Vogel RL, McElwee-Witmer S, Chen F, Nantermet PV, Kasparcova V, Leu CT, Zhang HZ, Duggan ME, Gentile MA, Hodor P, Pennypacker B, Masarachia P, Opas EE, Adamski SA, Cusick TE, Wang J, Mitchell HJ, Kim Y, Prueksaritanont T, Perkins JJ, Meissner RS, Hartman GD, Freedman LP, Harada S, Ray WJ. Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J. Biol. Chem., 285, 17054-17064 (2010).
34. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet. Gynecol., 85, 304-313 (1995).
35. Nantermet PV, Masarachia P, Gentile MA, Pennypacker B, Xu J, Holder D, Gerhold D, Towler D, Schmidt A, Kimmel DB, Freedman LP, Harada S, Ray WJ. Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogenregulated genetic pathways. Endocrinology, 146, 564-578 (2005).
36. Mobini Far HR, Agren G, Lindqvist AS, Marmendal M, Fahlke C, Thiblin I. Administration of the anabolic androgenic steroid nandrolone decanoate to female rats causes alterations in the morphology of their uterus and a reduction in reproductive capacity. Eur. J. Obstet. Gynecol. Reprod. Biol., 131, 189-197 (2007).
37. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest., 93, 63-69 (1994).
38. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH study investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med., 349, 1207-1215 (2003).
39. Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res., 26, 503-511 (2011).
40. Wronski TJ, Cintrón M, Dann LM. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif. Tissue Int., 43, 179-183 (1988).
41. Seedor JG, Quartuccio HA, Thompson DD. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J. Bone Miner. Res., 6, 339-346 (1991).
42. Yamamoto N, Takahashi HD, Tanizawa T, Endo N, Nishida S, Kinto N. Discrepancy of response of hPTH administration and its withdrawal between trabecular and cortical bone sites in OVX rats. Bone, 17, 279S-283S (1995).
43. Need AG, Morris HA, Hartley TF, Horowitz M, Nordin BE. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women. Calcif. Tissue Int., 41, 7-10 (1987).
44. Benéton MN, Yates AJ, Rogers S, McCloskey EV, Kanis JA. Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface. Clin. Sci., 81, 543-549 (1991).
45. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology, 58 (Suppl. 1), 101-107 (2001).